Mast cells express the high affinity receptor for IgE (FceRI) on the cell surface which plays a pivotal role in the development of allergic inflammation. FceRI is mainly expressed on mast cells and basophils as a tetramer of one a, one b and g chain homodimers. Aggregation of the FceRI on mast cells by bound IgE and multivalent antigens induces rapid release of preformed intragranular mediators such as histamine and heparin, newly synthesis of arachidonic acid metabolites, such as prostaglandins (PGs) and leukotrienes (LTs).
Mast cells express the high affinity receptor for IgE (FceRI) on the cell surface which plays a pivotal role in the development of allergic inflammation. FceRI is mainly expressed on mast cells and basophils as a tetramer of one a, one b and g chain homodimers. Aggregation of the FceRI on mast cells by bound IgE and multivalent antigens induces rapid release of preformed intragranular mediators such as histamine and heparin, newly synthesis of arachidonic acid metabolites, such as prostaglandins (PGs) and leukotrienes (LTs). 1) Activation of intracellular signaling is essential for these acute allergic reactions through FceRI. Namely, upon FceRI cross-linking, tyrosine phosphorylation of the b chain via activated-Lyn and subsequent phosphorylation of g chain and Syk by Lyn are immediately induced, which in turn leads to activation of phospholipase C (PLC)-g and linker for activation of T cells (LAT), intracellular Ca 2ϩ mobilization, activation of protein Kinase C (PKC) and mitogen activated protein (MAP) kinase family.
2) A large number of studies revealed that suppression of Ca 2ϩ responses, PKC and MAP kinase family members has substantial inhibitory effects on release of histamine and generation of arachidonic acid metabolite in mast cells. 3, 4) The dried roots of Euphorbia kansui L. (E. kansui) are known as "Kan Sui" in Chinese medicine and have been used as herbal remedy for cancer or edema in the mainland of China. 5) As for anti-tumor activity of E. kansui, it was reported that numerous diterpenes with an ingenol skeleton from the roots of the E. kansui suppress progression of cell cycle related to proliferation of cancer cells. 6) Recently, we found that 3-O-(2,3-dimethylbutanoyl)-13-O-decanoylingenol (abbreviated thereafter as DBDI) from E. kansui has a potent inhibitory effect on release of b-hexosaminidase in rat basophilc leukemia 2H3 cells (RBL-2H3) following FceRI cross-linking (unpublished data).
In this study, we investigated effects of DBDI on the activation of intracellular signaling pathways and the release of inflammatory chemical mediators in the bone marrow-derived mouse mast cells upon FceRI stimulation. Here, we report that DBDI-treated mast cells show a significant reduction of b-hexosaminidase release and eicosanoids synthesis when compared with non-treated cells. These suppressive actions of DBDI may be caused by inhibiting of intracellular signaling including Syk, PLC-g 2 , Ca 2ϩ responses and extracellular signal regulated kinase (ERK) 1/2. Our findings of the present study may provide useful information for antiallergic action of the DBDI against mast cell activation through FceRI.
MATERIALS AND METHODS
Chemical DBDI ( Fig. 1) was purified from the dried roots of E. kansui as described previously. 7) Briefly, the dried roots of E. kansui (15.1 kg) were extracted twice with 60% ethanol under reflux. Evaporation of the solvent from the combined extract under reduced pressure gave the 60% ethanol extract. The extract was dissolved and suspended in water and partitioned with chloroform, ethyl acetate, and nbutanol. DBDI was purified from chloroform fraction employing column chromatography and HPLC. The purified-DBDI was dissolved in 100% Dimethyl Sulfoxide (DMSO) (Wako Chemicals, Japan) at Ϫ20°C.
Reagents Anti rat b-chain mAb (the hybridoma (clone JRK) was kindly gifted by Dr. Juan Rivera at NIH, U.S.A.) was prepared in our laboratory. Polyclonal Abs to ERK1/2, phospho-ERK1/2 (Thr202/Tyr204), phospho-PLC-g 2 (Tyr1217) and phospho-Syk (Tyr525/526) were purchased from Cell Signaling Technology (Bevery, MA, U.S.A.). Antitrinitrophenyl (TNP) monoclonal IgE was purchased from Pharmingen (San Diego, CA, U.S.A.) and was labeled with fluorescein isothiocyanate (FITC). 4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP1) was purchased from Calbiochem (San Diego, CA, U.S.A.).
Mice Four-week-old C57BL/6j mice were purchased from Charles River Japan Inc. (Tokyo, Japan). All experiments were performed in accordance with the guide for the care and use of laboratory animals of Nihon University.
Cell Cultures Bone marrow-derived mouse mast cells (BMMC) were prepared from femur of C57BL/6j mice. Cells were cultured in the RPMI1640 (Sigma, St. Louis, MO, U.S.A.) supplemented with 10% FBS, and 5 ng/ml recombinant IL-3 (Peprotech, London, U.K.). After 4-week, BMMC were confirmed FceRI expression on the cell surface and then used for experiments.
Cell Stimulation BMMC (5ϫ10 6 ) were sensitized with anti-TNP IgE (1 mg/ml) in the absence of recombinant IL-3 at 37°C for 4 h. The IgE-sensitized cells were treated with 0-12.5 mg/ml of DBDI at 37°C for 30 min, and then washed twice with 1ϫTyrode's buffer (20 mM HEPES, pH 7.4, 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5.6 mM glucose, and 0.05% BSA). Cells were stimulated with 0-30 ng/ml of TNP-BSA (LSL, Tokyo, Japan) for indicated time periods.
Immunoblotting The stimulated cells (5ϫ10 6 ) were washed twice with ice-cold PBS and lysed in Tris Buffer Saline containing 1% Nonidet P-40, 60 mM Octyl-b-glucoside, 2 mM Phenylmethylsulphonylfluoride (PMSF), 10 mg/ml aprotinin, 2 mg/ml leupeptin and pepstatin A, 50 mM NaF and 1 mM sodium orthovanadate, for 30 min on ice. The lysates were centrifuged for 15 min at 14000ϫg. The samples were then boiled, separated on 10 or 12% SDS-PAGE, and transferred on to Immobilon-P membrane (Millipore, Bedford, MA, U.S.A.). The membrane was incubated with primary antibody and an appropriate secondary horseradish peroxidaseconjugated antibody. Signals were detected by enhanced chemiluminescence (Amersham Bioscience, Little Chalfont, U.K.). The immunoreactive bands were scanned to produce digital images that were quantified employing NIH Image software, and then fold induction was calculated by the relative amount of phospho-Syk, phospho-PLC-g 2 protein, phospho-ERK1/2 to each loading control proteins.
Measurement of [Ca

2؉
] i Mobilization The IgE-sensitized cells (5ϫ10 5 ) were incubated with 0-12.5 mg/ml of DBDI for 30 min, and then washed twice with 1ϫHank's balanced salt solution (HBSS). The cells were loaded with 16 mM Fluo-3AM and 8 mM Fura-RedAM (Invitrogen, Groningen, The Netherlands) in 1ϫHBSS for 20 min at 37°C. The cells were resuspended in 1ϫTyrode's buffer, and then changes of dye fluorescence upon addition of TNP-BSA (30 ng/ml) were evaluated employing flow cytometry. The [Ca 2ϩ ] i mobilization expressed as the ratio of Fluo-3AM/ Fura-RedAM (Dojindo, Kumamoto, Japan) fluorescence intensity.
b b-Hexosaminidase Release Assay Degranulation of mast cells was determined by b-hexosaminidase release. Briefly, cells (5ϫ10 5 ) were stimulated in 0.2 ml 1ϫTyrode's buffer at indicated concentrations of antigen at 37°C for 30 min. The cells were lysed with 1% Nonidet P-40 in the above-mentioned medium. The supernatants and the total cell lysates were incubated with 1.3 mg/ml of p-nitrophenil-N-acetyl-b-D-gulcopyranoside (Sigma) in 0.1 M sodium citrate buffer (pH 4.5) at 37°C for 40 min. The reaction was terminated by addition of 0.2 M glycine buffer (pH 10.7). The release of the product 4-p-nitrophenol was evaluated by optical absorbance at 405 nm.
Measurements of Eicosanoids Production Cell culture supernatants after FceRI stimulation were analyzed for LTC 4 , PGD 2 and PGE 2 by specific ELISA kits (Cayman Chemical, Ann Arbor, MI, U.S.A.) according to the manufacture's instructions.
Flow Cytometry For the evaluation of FceRI expression on the cell surface, BMMC (5ϫ10 5 ) were incubated with 1 mg/ml FITC-conjugated anti TNP IgE for 60 min at 4°C, and then with 12.5 mg/ml of DBDI or 0.1% DMSO for another 30 min at 37°C. In order to monitor apoptosis, cells (1ϫ10 5 ) were incubated with 1 mg/ml of FITC-labeled annexin V (Pharmingen) and 2.5 mg/ml of propidium iodide (Pharmingen) at room temperature for 15 min in the dark. Flow cytometric analyses were performed employing FACSCalibur (Becton-Dickinson, San Jose, CA, U.S.A.).
Statistical Analysis Williams multiple comparisons test was performed to determine statistical significance among the experimental groups; pϽ0.05 was considered significant.
RESULTS
Inhibition of b b-Hexosaminidase Release and Eicosaniods Synthesis by DBDI
To examine effects of the DBDI on release of preformed mediators from mast cells, we prepared BMMC from C57BL/6j mice. In the DBDI-treated BMMC, b-hexosaminidase (one of the preformed intragranullar enzymes) release induced by FceRI stimulation was inhibited in a dose-dependent manner ( Fig. 2A) . We next investigated whether DBDI suppresses secretion of LTC 4 , PGD 2 and PGE 2 , which are newly synthesized inflammatory mediators. As shown in Table 1 , production of LTC 4 , PGD 2 and PGE 2 induced by FceRI stimulation was also significantly inhibited with treatment of the DBDI. In DBDItreated resting BMMC, production of LTC 4 and PGD 2 was also inhibited at 12.5 mg/ml. These results suggest that the DBDI has severe suppressive effects on both the release of preformed mediators and the newly synthesis of eicosanoids in mast cells. Since ingenane-type diterpenes have been reported to induce apoptosis of intact murine thymocytes and Jurkat human T lymphocytes, 8, 9) we further evaluated cytotoxic effects of DBDI on BMMC. BMMC were cultured with 12.5 mg/ml of DBDI or 0.1% DMSO for 24 h. As shown in ] i elevation in a concentration-dependent manner (0-0.1 mg/ml) (Fig. 3A) , and this chemical completely blocked [Ca 2ϩ ] i increase in the FceRI-stimulated mast cells at concentrations of 0.5-12.5 mg/ml. This result appears in accordance with effects of DBDI entirely inhibiting b-hexosaminidase release and eicosanoids secretion at concentrations of 0.5-12.5 mg/ml. We next examined effects of DBDI on FceRI expression on BMMC because PMA can induce a rapid and significant decrease in FceRI expression on RBL-2H3 cells as an alternative pharmacological effect.
11) As shown in Fig. 3B , DBDI had no effect on the cell surface FceRI expression (Fig. 3B) . It is thereby concluded that DBDI has no potential to reduce the FceRI expression on BMMC at protein level, although effect of the compound on the gene expression for FceRI of the RBL-2H3 cells is unknown. Based on the above results shown in Figs. 2 and 3 , we hypothesized that DBDI directly suppresses activation of a variety of intracellular signals, which are necessary for [Ca 2ϩ ] i increase and mediators secretion induced by FceRI cross-linking.
DBDI Suppresses Activation of Syk and PLC-g g 2 in Mast Cells
Protein-tyrosine phosphorylation is early intracellular signaling event 12, 13) that initiates activation cascade resulting in inflammatory mediator release. We first examined effects of DBDI on whole cellular protein tyrosine phosphorylation in BMMC. In the BMMC treated with 0.5 mg/ml of DBDI, decrease of whole protein-tyrosine phosphorylation was not so much, but tyrosine phosphorylation of some proteins (marked with asterisks) was significantly reduced when compared with that of control cells (Fig. 4A) . Compared to PP1, DBDI inhibited tyrosine phosphorylation more strongly. Thus, DBDI is likely to have direct effects on mast cell signaling cascades.
To investigate the effects of DBDI on intracellular signaling of mast cells in more details, we further analyzed phosphorylation of Syk and PLC-g 2 which play important roles for [Ca 2ϩ ] i responses of mast cells. 14, 15) Western blotting analyses employing phospho-specific antibodies revealed that, upon FceRI cross-linking, tyrosine phosphorylation of Syk and PLC-g 2 was obviously reduced in the DBDI-treated BMMC when compared to that of the control cells (Fig. 4B) .
Effects of DBDI on Activation of ERK1/2 Activation of extracellular signal regulated kinase (ERK) 1/2 as well as [Ca 2ϩ ] i increase is required for eicosanoids synthesis in mast cells, 4) and the activation is mainly induced through Syk-mediated signaling pathway. 16) Figure 4B therefore suggests that ERK1/2 activation in the DBDI-treated mast cells might be reduced due to decrease of Syk activation, we examined phosphorylation of ERK1/2 in the DBDI-treated mast cells upon FceRI cross-linking. As expected, the DBDI-treated BMMC showed significant decrease of ERK1/2 phosphorylation when stimulated with IgE and antigen (Fig. 4C) . 
DISCUSSION
In the present study, we revealed that DBDI, one of ingenane-type diterpenes from E. kansui, significantly inhibits [Ca 2ϩ ] i increase b-hexosaminidase release, and synthesis of PGD 2 , PGE 2 and LTC 4 in the BMMC stimulated with IgE and multivalent antigen complex. Moreover, we demonstrated that DBDI inhibits activation of intracellular signaling molecules, including Syk, PLC-g 2 and ERK1/2. It is noteworthy that the inhibition of b-hexosaminidase release was observed only in the DBDI-treated RBL-2H3 cells when we performed screening of 11 ingenane-type diterpenes obtained from E. kansui (data not shown).
Increase of [Ca 2ϩ ] i is thought essential for preformed mediators release of mast cells upon FceRI engagement. 3, 17) As shown in Fig. 3A ] i increase by DBDI is due in part to reduction of extracellular Ca 2ϩ influx by inhibiting depletion of intracellular Ca 2ϩ storage, because DBDI clearly suppressed tyrosine phosphorylation of Syk and PLC-g 2 , which leads to IP3 production (Fig. 4B) .
In mast cells, Syk is thought to stimulate not only Ca 2ϩ responses via PLC-g but also Syk-LAT-ERK1/2 pathway. In fact, Syk-deficient mast cells fail to activate ERK1/2 when stimulated through FceRI. 21 ) Therefore, we consider that inhibition of ERK1/2 phosphorylation by DBDI might depend on suppression of Syk activation. Generally, ERK1/2 as well as [Ca 2ϩ ] i play essential roles for activation of Ca 2ϩ dependent-cytosolic phospholipase A 2 (cPLA 2 ), leading to arachidonic acid generation. 22, 23) Because DBDI significantly inhibits both Ca 2ϩ responses and ERK1/2 activation of mast cells, it is conceivable that DBDI may suppress arachidonic acid generation by inhibiting cPLA 2 activation.
The primary target of DBDI in a series of mast cell signaling upon aggregation of the FceRI is currently unknown. In the FceRI-stimulated human basophils, significant time lag of [Ca 2ϩ ] i mobilization is caused by inhibiting Lyn activation with a specific inhibitor, PP1. 24) In addition, Lyn-deficient mast cells also show a delayed [Ca 2ϩ ] i mobilization when compared with wild-type mast cells. 25) In the present study, it was similarly observed that DBDI induces a significant time lag of [Ca 2ϩ ] i mobilization of BMMC at low concentrations. Collectively, it is suggested that DBDI may also suppress Lyn kinase activity in relation to initiation of mast cell signaling. These findings of the present study suggest that DBDI acts as a potent inhibitor for IgE-mediated production of inflammatory chemical mediators in vitro.
However, DBDI itself induces a harmful effect such as convulsion in mice when 25 mg/kg of DBDI was administered by intravenous injection (data not shown), we therefore consider that administration of DBDI to experimental animals should be carefully performed for in vivo analyses of DBDI. It will be necessary that optimal dose and methods of DBDI administration into experimental animals are further examined in future investigations.
